Jim Weissman

Jim Weissman is principal of JBW Consulting, where he advises biopharmaceutical companies on business strategy and corporate development. He serves as an independent director for Cerberus Therapeutics, Constructive Bio, and Telesis Bio. Previously, he spent more than a decade at Dicerna Pharmaceuticals, serving as EVP, COO, and CBO. Dicerna, a developer of RNA interference (RNAi) based medicines, was acquired by Novo Nordisk for $3.3 billion in 2021. During his time at Dicerna, the company expanded its GalXC RNAi platform to support nearly 20 development programs and formed six collaborations with Alexion, Alnylam, Boehringer Ingelheim, Lilly, Novo Nordisk, and Roche, generating more than $1 billion in upfront, milestone, and related payments by the time of the acquisition. He also supported the company’s financings, including its 2014 IPO.

Before joining Dicerna, Jim was vice president of business development at MannKind Corporation. He previously held business development and marketing roles at Pfizer in Tokyo and commercial and leadership positions at Pharmacia Biotech across the United States, Sweden, Japan, and the United Kingdom. Jim earned a B.S. in chemistry from Bates College.